{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:58:23Z","timestamp":1769115503220,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Education, Universities and Research","award":["CTN01_00177_817708"],"award-info":[{"award-number":["CTN01_00177_817708"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biosensors"],"abstract":"<jats:p>Background: Antineoplastic agents represent the most common class of drugs causing Adverse Drug Reactions (ADRs). Mutant alleles of genes coding for drug-metabolizing enzymes are the best studied individual risk factors for these ADRs. Although the correlation between genetic polymorphisms and ADRs is well-known, pharmacogenetic tests are limited to centralized laboratories with expensive or dedicated instrumentation used by specialized personnel. Nowadays, DNA chips have overcome the major limitations in terms of sensibility, specificity or small molecular detection, allowing the simultaneous detection of several genetic polymorphisms with time and costs-effective advantages. In this work, we describe the design of a novel silicon-based lab-on-chip assay able to perform low-density and high-resolution multi-assay analysis (amplification and hybridization reactions) on the In-Check platform. Methods: The novel lab-on-chip was used to screen 17 allelic variants of three genes associated with adverse reactions to common chemotherapeutic agents: DPYD (Dihydropyrimidine dehydrogenase), MTHFR (5,10-Methylenetetrahydrofolate reductase) and TPMT (Thiopurine S-methyltransferase). Results: Inter- and intra assay variability were performed to assess the specificity and sensibility of the chip. Linear regression was used to assess the optimal hybridization temperature set at 52 \u00b0C (R2 \u2248 0.97). Limit of detection was 50 nM. Conclusions: The high performance in terms of sensibility and specificity of this lab-on-chip supports its further translation to clinical diagnostics, where it may effectively promote precision medicine.<\/jats:p>","DOI":"10.3390\/bios10120202","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T09:17:58Z","timestamp":1607505478000},"page":"202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents"],"prefix":"10.3390","volume":"10","author":[{"given":"Rosario","family":"Iemmolo","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami, 18-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"La Cognata","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami, 18-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Morello","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami, 18-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Guarnaccia","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami, 18-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariamena","family":"Arbitrio","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, 88100 Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Alessi","sequence":"additional","affiliation":[{"name":"Analog, MEMS &amp; Sensor Group Health Care Business Development Unit, STMicroelectronics, Stradale Primosole, 50-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-1792","authenticated-orcid":false,"given":"Sebastiano","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami, 18-95126 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"ref_1","unstructured":"Forman, D., Bray, F., Brewster, D., Gombe Mbalawa, C., Kohler, B., Pi\u00f1eros, M., Steliarova-Foucher, E., Swaminathan, R., and Ferlay, J. (2013). Cancer Incidence in Five Continents, IARC. Electronic Version."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejcsup.2008.06.021","article-title":"Pharmacogenetics in oncology","volume":"6","author":"Danesi","year":"2008","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00002018-200124020-00001","article-title":"What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?","volume":"24","author":"Ozdemir","year":"2001","journal-title":"Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","article-title":"Clinical application of pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00103-013-1822-2","article-title":"Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics","volume":"56","author":"Stingl","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundh. Gesundh."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200645030-00003","article-title":"Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer","volume":"45","author":"Bosch","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fgene.2012.00229","article-title":"Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: Comparison with caucasian and asian populations","volume":"3","author":"Roco","year":"2012","journal-title":"Front. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chang, W.-C., Tanoshima, R., Ross, C.J., and Carleton, B.C. (2020). Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. Annu. Rev. Pharmacol. Toxicol., 61.","DOI":"10.1146\/annurev-pharmtox-030920-025745"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","article-title":"Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments","volume":"20","author":"Lauschke","year":"2017","journal-title":"AAPS J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Arbitrio, M., Scionti, F., Di Martino, M.T., Caracciolo, D., Pensabene, L., Tassone, P., and Tagliaferri, P. (2020). Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice. Clin. Transl. Sci.","DOI":"10.1111\/cts.12869"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00216-020-02593-w","article-title":"Label-free graphene oxide\u2013based SPR genosensor for the quantification of microRNA21","volume":"412","author":"Mujica","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liu, R.H., and Lee, A.P. (2007). Integrated DNA Biochips: Past, Present and Future. Integrated Biochips for DNA Analysis, Springer.","DOI":"10.1007\/978-0-387-76759-8"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hardiman, G. (2008). Applications of microarrays and biochips in pharmacogenomics. Pharmacogenomics in Drug Discovery and Development, Springer.","DOI":"10.1007\/978-1-59745-205-2_2"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11008-005-0050-8","article-title":"Development of a biochip for analyzing polymorphism of the biotransformation genes","volume":"39","author":"Glotov","year":"2005","journal-title":"Mol. Biol."},{"key":"ref_18","first-page":"9","article-title":"Biochips-tools of 21st century medicine","volume":"58","year":"2006","journal-title":"Versicherungsmedizin"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.snb.2012.09.068","article-title":"In-Check system: A highly integrated silicon Lab-on-Chip for sample preparation, PCR amplification and microarray detection of nucleic acids directly from biological samples","volume":"187","author":"Petralia","year":"2013","journal-title":"Sens. Actuators B Chem."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Palmieri, M., Alessi, E., Conoci, S., Marchi, M., and Panvini, G. (2008). Developments of the in-check platform for diagnostic applications. Microfluidics, BioMEMS, and Medical Microsystems VI, International Society for Optics and Photonics.","DOI":"10.1117\/12.778331"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8100","DOI":"10.3390\/s120608100","article-title":"Novel biochip platform for nucleic acid analysis","volume":"12","author":"Pernagallo","year":"2012","journal-title":"Sensors"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Guarnaccia, M., Iemmolo, R., San Biagio, F., Alessi, E., and Cavallaro, S. (2018). Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform. Sensors, 18.","DOI":"10.3390\/s18010131"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3130469","DOI":"10.1155\/2016\/3130469","article-title":"Biosensors in Health Care: The Milestones Achieved in Their Development towards Lab-on-Chip-Analysis","volume":"2016","author":"Patel","year":"2016","journal-title":"Biochem. Res. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygeno.2014.02.003","article-title":"Is this the real time for genomics?","volume":"103","author":"Guarnaccia","year":"2014","journal-title":"Genomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1021\/acssensors.0c00052","article-title":"Nucleic Acid Quantitation with Log\u2013Linear Response Hybridization Probe Sets","volume":"5","author":"Wu","year":"2020","journal-title":"ACS Sens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11103-005-6173-4","article-title":"A Microarray-based Detection System for Genetically Modified (GM) Food Ingredients","volume":"61","author":"Leimanis","year":"2006","journal-title":"Plant Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.2006.02713.x","article-title":"Drug development in oncology: Classical cytotoxics and molecularly targeted agents","volume":"62","author":"Kummar","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"Vreken","year":"1999","journal-title":"Hum. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Garziera, M., Bidoli, E., Cecchin, E., Mini, E., Nobili, S., Lonardi, S., Buonadonna, A., Errante, D., Pella, N., and D\u2019Andrea, M. (2015). HLA-G 3\u2019UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144000"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_33","first-page":"556","article-title":"DPYD* 6 plays an important role in fluoropyrimidine toxicity in addition to DPYD* 2A and c. 2846A> T: A comprehensive analysis in 1254 patients","volume":"19","author":"Cinieri","year":"2019","journal-title":"Pharm. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41416-019-0423-8","article-title":"The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study","volume":"120","author":"Iachetta","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mgene.2015.12.002","article-title":"Polymorphisms of glutathione S-transferase and methylenetetrahydrofolate reductase genes in Moldavian patients with ulcerative colitis: Genotype-phenotype correlation","volume":"7","author":"Varzari","year":"2016","journal-title":"Meta Gene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/annonc\/mdf322","article-title":"Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate","volume":"13","author":"Chiusolo","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","article-title":"Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: A meta-analysis","volume":"33","author":"Yang","year":"2012","journal-title":"Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00008571-200412000-00001","article-title":"Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients","volume":"14","author":"Etienne","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.21873\/anticanres.14428","article-title":"Association of C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer","volume":"40","author":"Chinchilla","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FPC.0b013e3283352860","article-title":"Very important pharmacogene summary: Thiopurine S-methyltransferase","volume":"20","author":"Wang","year":"2010","journal-title":"Pharm. Genom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.4","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update","volume":"93","author":"Relling","year":"2013","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biosensors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6374\/10\/12\/202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:42:53Z","timestamp":1760179373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6374\/10\/12\/202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["bios10120202"],"URL":"https:\/\/doi.org\/10.3390\/bios10120202","relation":{},"ISSN":["2079-6374"],"issn-type":[{"value":"2079-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}